BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Expectations Audits

UPS: The Margin Story the Filings Tell vs. the One the Market Is Buying

Moe Alsumidaie, MBA, MSF by Moe Alsumidaie, MBA, MSF
August 12, 2026
in Expectations Audits
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

A stock trading at a trailing earnings multiple well above its own decade average. A business whose net margin has been cut in half over four years. Those two facts should not coexist without a very good explanation, and right now UPS is betting its entire investment case on one.

For most of its history, UPS was the quiet giant of American logistics: a brown-truck empire that grew steadily by moving more of everything. Then came the pandemic surge, a labor contract that cost more than anyone planned, and a deliberate decision to shrink its biggest customer relationship. The 10-K for fiscal year 2025 shows a company whose revenue has fallen meaningfully from its 2022 peak, with a net margin of 6.3%, less than half the 13.2% it posted in 2021. The question every saver should ask is whether the current price reflects a business in managed transition or one in structural decline.

In one breath

The filed numbers show UPS deliberately trading volume for margin quality, with domestic pricing power now outrunning costs. The stock is priced as if that transition succeeds cleanly and quickly. The open question is whether volumes recover fast enough to justify a multiple that sits well above the company’s own decade median.

Claim one: “The Amazon exit is complete and the pain is behind us”

This is the most repeated line in current coverage, and the filings mostly support it. CEO Carol Tomé said on the July 28, 2026 earnings call that the company has successfully completed its “Amazon glide down,” removing roughly 2 million daily delivery pieces and billions in related expenses over eighteen months. The 10-Q for the quarter ended June 30, 2026 shows U.S. Domestic revenue per piece rose sharply year over year in Q2, and domestic operating margin doubled from the prior quarter. That is real pricing power, and it is filed, not projected.

BullScope TerminalYou just read UPS’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

But “behind us” is doing heavy lifting. Total consolidated average daily volume still fell year over year in Q2 2026, and TIKR notes that management guided U.S. Domestic daily volume to remain negative year over year through Q3 2027. A business earning more per package while shipping fewer packages is not yet a business that has replaced what it gave up. The pain of lower revenue is filed history; the recovery in volume is still a forecast.

For a household analogy: imagine a bakery that stopped selling cheap wholesale bread to one giant grocery chain, raised prices on its retail loaves, and now earns more per loaf but sells fewer loaves overall. The margin math looks better. The revenue line does not, yet.

Claim two: “The cost program is delivering real savings”

Here the filings and the commentary line up well, with one important asterisk. The Q2 2026 press release states UPS achieved approximately $1.2 billion in cost-reduction benefits in the first half of 2026, targeting $3 billion for the full year through its “Network Reconfiguration and Efficiency Reimagined” program. Automation now handles a significantly larger share of U.S. volume than a year earlier, and the company closed 93 buildings in 2025 and continued closures into the first half of 2026.

The asterisk is the GAAP charge sitting in the same quarter. The Q2 2026 10-Q shows after-tax transformation charges of $891 million, mostly employee separation costs, which collapsed the reported GAAP operating margin to 4.1% even as the adjusted figure ran at 9.2%. That gap, more than five percentage points, is not accounting noise. It represents real cash paid to real workers leaving the company. The $3 billion in annual savings the company targets is a gross figure; the cost of getting there is being paid now and is material.

Barclays, which MarketBeat reports maintains an Underweight rating with an $80 valuation estimate, argues that labor costs and regional competition will keep pressure on margins even after the restructuring is complete. Goldman Sachs has reportedly added UPS to a conviction-buy list, with TIKR characterizing the thesis as “skepticism is already priced in”; readers should consult the primary Goldman research note for the full argument and disclosures. Both views are coherent. The filed numbers show the savings are arriving; they do not yet show whether the savings survive the competitive pressure that follows.

BullScope TerminalUPS was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

Claim three: “The valuation is reasonable given the recovery”

This is where the math and the mood diverge most sharply. “The math” is what the filed fundamentals justify on their own terms; “the mood” is the price the market is currently willing to pay. Right now the mood is generous.

GuruFocus puts the trailing twelve-month P/E at 19.4 as of early August 2026, reflecting depressed GAAP earnings from transformation charges. Management’s own full-year 2026 EPS guidance, cited in the Q2 2026 earnings release, implies a forward multiple near 14.5 times at the current share price, still above the company’s decade-median multiple of 11.6 times. So the stock is priced above its own historical norm on forward earnings that themselves assume the restructuring works as planned.

There is also a dividend question worth naming plainly. The Q2 2026 10-Q shows free cash flow of $380 million for the quarter, while the company expects to pay roughly $5.4 billion in dividends for the full year. That is a dividend running at more than three times the pace of recent quarterly cash generation. The 10-K for 2025 shows a long-term debt load equal to roughly a quarter of annual revenue. The data cannot tell us whether the dividend is sustainable without seeing the full-year cash flow; free cash flow in the back half of 2026 is therefore the filed metric most likely to resolve the dividend sustainability question one way or the other.

Reading the numbers

  • Q2 2026 consolidated revenue: $22.8 billion. What it is: total sales across all UPS divisions in one quarter. What it means here: revenue beat analyst expectations of $21.84 billion, per Barchart, but is still running below the pace needed to reach the 2022 peak. Everyday version: a shop that used to ring $100 at the register is now ringing about $91, and this quarter’s result was better than the cashier expected.
  • U.S. Domestic operating margin: 8.0% in Q2 2026, vs. 4.0% in Q1 2026. What it is: of every dollar of domestic delivery revenue, 8 cents survived after operating costs. What it means here: the sequential jump is the clearest filed evidence that the pricing strategy is working. Everyday version: a delivery driver who used to keep 4 cents of every dollar earned now keeps 8, after the route got shorter and the stops got more profitable.
  • GAAP vs. adjusted operating margin: 4.1% vs. 9.2% in Q2 2026. What it is: GAAP includes all costs including one-time restructuring charges; adjusted strips them out. What it means here: the $891 million in transformation charges is real money, not a footnote. Everyday version: a household that earned $5,000 this month but paid $2,000 in moving costs to get into a cheaper apartment, the new rent is lower but this month’s budget still hurts.
  • Long-term debt: $22.8 billion as of December 31, 2025. What it is: money borrowed and owed over more than one year. What it means here: at roughly a quarter of annual revenue, this is a meaningful load on a company also paying $5.4 billion a year in dividends. Everyday version: a household earning $90,000 a year carrying $23,000 in long-term debt while also committed to $5,400 in annual payments to family members.

Sources

  • UPS 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
  • UPS 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
  • UPS Q2 2026 earnings press release
  • UPS Q2 2026 earnings newsroom release
  • UPS Q2 2026 earnings call transcript (Finsee)
  • Barchart: UPS Q2 2026 beat and raise
  • GuruFocus: UPS trailing P/E
  • MarketBeat: UPS analyst ratings and valuation estimates
  • TIKR: UPS post-earnings analysis
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read UPS’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie, MBA, MSF

Moe Alsumidaie, MBA, MSF

Moe Alsumidaie, MBA, MSF is the Chief Editor of BullScope. Trained in finance, with a Master of Science in Finance and an MBA, he spent years inside large public healthcare companies including Abbott, Genentech, and Roche, learning how the businesses behind the filings actually run. As a journalist and Chief Editor of The Clinical Trial Vanguard, his reporting has appeared in Applied Clinical Trials, The American Journal of Managed Care, and CNET, and has been cited in U.S. Supreme Court proceedings. At BullScope he brings those disciplines together: every note starts in the SEC filings, runs through published methodology, and shows its work.

Recommended For You

Amgen: The Stock Is Priced for a Future the Filings Haven’t Promised Yet

by Moe Alsumidaie, MBA, MSF
September 8, 2026
0

For most of the past decade, Amgen was a reliable but slow-moving machine: a biotech giant that grew revenues at roughly the pace of the broader economy, collected...

Read moreDetails

A 95% Gross Margin and a P/S Below Its Own Median: PTC Therapeutics’ Profitability Flip Is Real, and the Valuation Gap Raises Questions

by Moe Alsumidaie, MBA, MSF
September 4, 2026
0

In one breath PTC Therapeutics spent the better part of a decade burning cash on a pipeline that mostly disappointed. Then, in the twelve months through the fiscal...

Read moreDetails

Moderna at 28 Times Sales: One Trial Result Is Doing a Lot of Work

by Moe Alsumidaie, MBA, MSF
September 3, 2026
0

Before anything else Moderna's filed revenue has fallen every year since 2022, and the company is burning through roughly $600 million a quarter. The stock, at $150.81, prices...

Read moreDetails

United Therapeutics: The Stock Is Priced for Stagnation. The Filings Tell a Different Story.

by Moe Alsumidaie, MBA, MSF
September 1, 2026
0

Two facts about United Therapeutics sit side by side right now and refuse to make peace. The company has grown earnings per share from $11.54 in 2020 to...

Read moreDetails

Biogen: The Stock That Priced In a Recovery the Margins Haven’t Filed Yet

by Moe Alsumidaie, MBA, MSF
September 1, 2026
0

Five years ago, Biogen's stock briefly traded above $425 on the back of an Alzheimer's drug that Medicare ultimately refused to cover. Today the stock sits near $218,...

Read moreDetails
Next Post

Evidence Sheet: Tonix Pharmaceuticals Holding (TNXP)

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Evidence Sheet: Moderna (MRNA)

September 3, 2026

Evidence Sheet: UnitedHealth Group (UNH)

September 4, 2026

The Margin That Vanished: Meta’s Q2 Call vs. the Filed Record

August 5, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.